Moreover, inhibitors of the poly (ADP-ribose) polymerase (PARPi) have been demonstrated to be effective in germline and somatic BRCA1- or BRCA2-mutated OCs [9,10,11], except for Niraparib that has been shown to be effective regardless of the presence of BRCA1/2 variants or the homologous recombination deficiency (HRD) status [12]. Here, BRCA1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.